Project: Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics
| Acronym | Cardio-Oncology (Reference Number: 12. JTC-2016_164) |
| Duration | 01/09/2017 - 31/08/2020 |
| Project Topic | Cardiac dysfunction leading to heart failure can result from anticancer treatments. The ultimate goal of the Cardio-Oncology project is to minimize adverse cardiotoxic effects of anticancer treatments, which will enable clinicians to fully exploit the benefits of modern cancer therapy. The development of novel and more effective and safe cardio-protective therapeutics will reduce the risk of mortality and improve quality of life of patients with anticancer drug-induced cardiotoxicity. In addition, by identifying novel and reliable biomarkers for early detection of cardiotoxicity, the consortium ensures that treatment with the novel cardio-protective therapeutic will be specifically used in high-risk patient subgroups. |
| Network | ERA-CVD |
| Call | ERA-CVD Joint Transnational Call 2016 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | CNRS, University of Strasbourg, UMR7242 | Coordinator | France |
| 2 | European Institute of Oncology | Partner | Italy |
| 3 | MIRA Institute, University of Twente, the Netherlands, | Partner | Netherlands |
| 4 | Institute of Structural Biology, Helmholtz Zentrum München (HMGU) | Partner | Germany |
| 5 | NOBEL Pharm. ULKAR HOLDING A.S. | Partner | Türkiye |
| 6 | National Chung Cheng University | Partner | Taiwan |